NCT06412848 2026-02-24
JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Active not recruiting
Clinical Trials
7 trialsNCT05366725 2025-12-02
A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Completed
NCT05431777 2025-04-01
A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Completed
NCT04822350 2025-01-27
AVENANCE
Pfizer
Completed
NCT05012865 2023-12-06
Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART)
Pfizer
Completed
NCT04555603 2023-11-21
Axitinib Therapy Management Study
Pfizer
Withdrawn
NCT05568407 2023-07-13
A Study of Avelumab in Real-World Treatment for Patients With Advanced or Metastatic Urothelial Cancer
Pfizer
Terminated